Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 28, 2026

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

Targeting the B cell in vasculitis.

Michael Walsh1, David Jayne

  • 1Vasculitis Clinic, Addenbrooke's Hospital, Hills Road, Box 118, Cambridge, CB2 2QQ, UK. mwwalsh@ucalgary.ca

Pediatric Nephrology (Berlin, Germany)
|October 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-stapling versus double-stapling technique for rectal anastomosis-meta-analysis.

BJS open·2026
Same author

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab.

Frontiers in medicine·2026
Same author

Update on therapeutic approaches in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Long-term risk of malignancies in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Radiological staging clinical decision support model for rectal cancer lymph node metastasis detection on MRI.

BMC cancer·2026
Same author

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.

Clinical pharmacology and therapeutics·2026
Same journal

Atypical renal phenotype with tubular proteinuria and hypercalciuria in siblings with nail-patella syndrome: evidence for a dual genetic diagnosis.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Blood pressure control in pediatric hemodialysis: data from the SCOPE collaborative.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Correlation between urinary soluble CD163 and endocapillary proliferation and fibrinoid necrosis in IgA vasculitis with nephritis.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

The role of urinary trehalase levels in the early diagnosis of acute kidney injury in dehydrated children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Neuron-specific enolase and brain-derived neurotrophic factor as developmental neurovascular markers in chronic kidney disease and kidney transplantation.

Pediatric nephrology (Berlin, Germany)·2026
See all related articles

Severe vasculitis treatments cause toxicities, especially in children. B-cell therapies like rituximab show promise for autoimmune diseases, but more data is needed to compare efficacy and safety against traditional treatments.

Area of Science:

  • Pediatric rheumatology
  • Immunology
  • Autoimmune diseases

Background:

  • Severe vasculitides, including ANCA-associated vasculitis, pose treatment challenges due to short- and long-term toxicities.
  • Refractory and relapsing disease necessitate prolonged exposure to harsh therapies, particularly in pediatric patients.
  • B cells are implicated in vasculitis pathogenesis, suggesting they are a viable therapeutic target.

Purpose of the Study:

  • To explore the role of B-cell targeted therapies in managing vasculitis.
  • To evaluate the potential of rituximab as a treatment for vasculitis.
  • To identify the need for comparative efficacy and safety data for B-cell therapies.

Main Methods:

  • Review of existing literature on B-cell targeted therapies for vasculitis.

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Experiment Videos

Last Updated: Jun 28, 2026

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

  • Analysis of rituximab's role in adult vasculitis treatment.
  • Identification of gaps in randomized controlled trial data.

    • Main Results:

    • Rituximab shows potential as a treatment for vasculitis in adults.
    • Limited randomized evidence exists comparing rituximab to cyclophosphamide for efficacy and toxicity.
    • Long-term safety data for rituximab in vasculitis is lacking.

    Conclusions:

    • B-cell targeted therapies, including rituximab, represent a promising avenue for vasculitis treatment with potentially improved toxicity profiles.
    • Further research, including randomized controlled trials, is crucial to establish the efficacy and safety of rituximab and other B-cell therapies.
    • Development of novel B-cell-directed therapies may offer alternatives or adjuncts to current vasculitis management strategies.